Summit Therapeutics reported mixed Phase III data for ivonescimab combined with chemotherapy in lung cancer across geographic regions. The drug demonstrated a 45% reduction in tumor progression risk for patients in China, attaining statistical significance. However, the same combination failed to meaningfully reduce progression risk in North American and European populations, raising concerns over regulatory approval prospects in these markets. These discrepancies highlight potential biological or trial design differences impacting drug efficacy across populations.